Pharmacological strategies that affect HIF-1 in the ischemic brain: Focus on hydroxylases activity and protein kinase pathways

Current Signal Transduction Therapy

Volumn 6, Issue 2, 2011, Pages 237-248

  Chánez Cárdenas, María Elena ^a   Espinoza Rojo, Mónica ^b   Rivera Rodríguez, José A ^a,b   Aguilera, Penélope ^a  

^a NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

Author keywords

Cerebral ischemia; HIF 1alpha; MAPK ERK; PI 3K Akt; Prolyl hydroxylases inhibitors

Indexed keywords

3,4 DIHYDROBENZOATE; BAICALEIN; BERGAMOT OIL; CLIOQUINOL; COBALT CHLORIDE; DEFEROXAMINE; ETHYL 3,4 DIHYDROBENZOATE; GINKGOLIDE A; GINKGOLIDE B; GINKGOLIDE C; GINKGOLIDE J; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N,N,N',N' TETRAKIS(2 PYRIDYLMETHYL)ETHYLENEDIAMINE; NEUROPROTECTIVE AGENT; OXYGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROLINE DERIVATIVE; PROPOFOL; PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; SELENITE; TM 6008; TM 6089; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

ANGIOGENESIS; ARTICLE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DISEASE SEVERITY; DRUG ABSORPTION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENE OVEREXPRESSION; HUMAN; HYDROXYLATION; HYPOXIA; MORBIDITY; MORTALITY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REGULATORY MECHANISM; SINGLE DRUG DOSE; UPREGULATION;

EID: 79957931989     PISSN: 15743624     EISSN: 15743624     Source Type: Journal    
DOI: 10.2174/157436211795660061     Document Type: Article

References (99)

1. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22: 391-7. Review. (Pubitemid 29453643)
2. Bickler PE, Donohoe PH. Adaptive responses of vertebrate neurons to hypoxia. J Exp Biol 2002; 205: 3579-86. (Pubitemid 36010745)
3. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003; 23: 9361-74. (Pubitemid 37499822)
4. Tanaka T, Wiesener M, Bernhardt W, Eckardt KU, Warnecke C. The human HIF (hypoxia-inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene induction. Biochem J 2009; 424: 143-51.
5. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006; 70: 1469-80. Review.
6. Galbán S, Gorospe M. Factors interacting with HIF-1alpha mRNA: novel therapeutic targets. Curr Pharm Des 2009; 15: 3853-60. Review.
7. Minet E, Michel G, Mottet D, Raes M, Michiels C. Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and activation. Free Radic Biol Med 2001; 31: 847-55. Review. (Pubitemid 32925082)
8. Freeman RS, Barone MC. Targeting hypoxia-inducible factor (HIF) as a therapeutic strategy for CNS disorders. Curr Drug Targets CNS Neurol Disord 2005; 4: 85-92. Review. (Pubitemid 41403317)
9. Giaccia A, Siim BG, Johnson RS. HIF-1 as a target for drug development. Nat Rev Drug Discov 2003; 2: 803-11. Review. (Pubitemid 37361812)
10. Shi H. Hypoxia inducible factor 1 as a therapeutic target in ischemic stroke. Curr Med Chem 2009; 16: 4593-600. Review.
11. Nagle DG, Zhou YD. Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1). Curr Pharm Des 2006; 12: 2673-88. Review.
12. Aguilera P, Vázquez-Contreras E, Gómez-Martínez CD, Chánez- Cárdenas ME. Hypoxia Inducible Factor-1 as a Therapeutic Target in Cerebral Ischemia. Current Signal Transduction Therapy 2009; 4: 162-173.
13. Rocha S. Gene regulation under low oxygen: holding your breath for transcription. Trends Biochem Sci 2007; 32: 389-97. (Pubitemid 47126857)
14. Stolze IP, Mole DR, Ratcliffe PJ. Regulation of HIF: prolyl hydroxylases. Novartis Found Symp 2006; 272: 15-25.
15. Appelhoff RJ, Tian YM, Raval RR, et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J Biol Chem 2004; 279: 38458-65. (Pubitemid 39295997)
16. Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol 2006; 41: 68-77. (Pubitemid 43964933)
17. Pocock R, Hobert O. Oxygen levels affect axon guidance and neuronal migration in Caenorhabditis elegans. Nat Neurosci 2008; 11: 894-900.
18. Nangaku M, Izuhara Y, Takizawa S, et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 2007; 27: 2548-54. (Pubitemid 350158904)
19. Kasiganesan H, Sridharan V, Wright G. Prolyl hydroxylase inhibitor treatment confers whole-animal hypoxia tolerance. Acta Physiol (Oxf) 2007; 190: 163-9. (Pubitemid 46776396)
20. Zhong Z, Ramshesh VK, Rehman H, et al. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2008; 295:G823-32.
21. Chu, PWY, Beart PM, Jones, NM. Preconditioning protects against oxidative injury involving hypoxia-inducible factor-1 and vascular endothelial growth factor in cultured astrocytes. Eur J Pharmacol 2010; 633:24-32.
22. Warnecke C, Griethe W, Weidemann A, et al. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 2003; 17:1186-8.
23. Siddiq A, Ayoub IA, Chavez JC, et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 2005; 280: 41732-43. (Pubitemid 41832236)
24. Cohen AR. New Advances in Iron Chelation Therapy. Hematology Am Soc Hematol Educ Program 2006; 42-7.
25. Keberle H: The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964;119:758-768
26. Palmer C, Roberts RL, Bero C: Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats. Stroke 1994; 25:1039-1045 (Pubitemid 24130313)
27. Li YX, Ding SJ, Xiao L, Guo W, Zhan Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 2008; 24: 89-95. (Pubitemid 351738284)
28. Chu K, Jung KH, Kim SJ, et al. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res 2008; 1207: 182-92.
29. van der Kooij MA, Groenendaal F, Kavelaars A, Heijnen CJ, van Bel F. Combination of deferoxamine and erythropoietin: therapy for hypoxia-ischemia- induced brain injury in the neonatal rat? Neurosci Lett 2009; 451: 109-13.
30. Hishikawa T, Ono S, Ogawa T, Tokunaga K, Sugiu K, Date I. Effects of deferoxamine-activated hypoxia-inducible factor-1 on the brainstem after subarachnoid hemorrhage in rats. Neurosurgery 2008; 62: 232-40; discussion 240-1. (Pubitemid 351640346)
31. Jones NM, Kardashyan L, Callaway JK, Lee EM, Beart PM. Longterm functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desferrioxamine against hypoxicischemic injury in neonatal rats. Pediatr Res 2008; 63: 620-4.
32. Chi OZ, Hunter C, Liu X, Weiss HR. Effects of deferoxamine on blood-brain barrier disruption and VEGF in focal cerebral ischemia. Neurol Res 2008; 30: 288-93. (Pubitemid 351769424)
33. Freret T, Valable S, Chazalviel L, et al. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci 2006; 23: 1757-65.
34. Choi KO, Lee T, Lee N, et al. Inhibition of the catalytic activity of hypoxia-inducible factor-1alpha-prolyl-hydroxylase 2 by a MYNDtype zinc finger. Mol Pharmacol 2005; 68: 1803-9. (Pubitemid 41654363)
35. Choi SM, Choi KO, Lee N, Oh M, Park H. The zinc chelator, N,N,N′,N′-tetrakis (2-pyridylmethyl) ethylenediamine, increases the level of nonfunctional HIF-1alpha protein in normoxic cells. Biochem Biophys Res Commun 2006; 343: 1002-8.
36. Kim I, Kim CH, Seo GH, et al. Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes. Neuroreport 2008; 19: 1063-6.
37. Kaczmarek M, Cachau RE, Topol IA, Kasprzak KS, Ghio A, and Salnikow K. Metal Ions-Stimulated Iron Oxidation in Hydroxylases Facilitates Stabilization of HIF-1a Protein. Toxicol Sci 2009; 107: 394-403.
38. Jung JY, Mo HC, Yang KH, et al. Inhibition by epigallocatechin gallate of CoCl2-induced apoptosis in rat PC12 cells. Life Sci 2007; 80: 1355-63.
39. Jung JY, Roh KH, Jeong YJ, et al. Estradiol protects PC12 cells against CoCl2-induced apoptosis. Brain Res Bull 2008; 76: 579-85.
40. Tan XL, Huang XY, Gao WX, et al. CoCl2-induced expression of p300 promotes neuronal-like PC12 cell damage. Neurosci Lett 2008; 441: 272-6.
41. Caltana L, Merelli A, Lazarowski A, Brusco A. Neuronal and glial alterations due to focal cortical hypoxia induced by direct cobalt chloride (CoCl2) brain injection. Neurotox Res 2009; 15: 348-58.
42. Aminova LR, Chavez JC, Lee J, et al. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem 2005; 280: 3996-4003. (Pubitemid 40223869)
43. Li L, Qu Y, Mao M, Xiong Y, Mu D. The involvement of phosphoinositid 3-kinase/Akt pathway in the activation of hypoxiainducible factor-1alpha in the developing rat brain after hypoxiaischemia. Brain Res 2008; 1197: 152-8.
44. Li L, Xiong Y, Qu Y, et al. The requirement of extracellular signalrelated protein kinase pathway in the activation of hypoxia inducible factor 1 alpha in the developing rat brain after hypoxiaischemia. Acta Neuropathol 2008; 115: 297-303.
45. Alvarez-Tejado M, Alfranca A, Aragonés J, Vara A, Landázuri MO, del Peso L. Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension. J Biol Chem 2002; 277:13508-17. (Pubitemid 34967948)
46. Zhang L, Qu Y, Yang C, et al. Signaling pathway involved in hypoxia-inducible factor-1alpha regulation in hypoxic-ischemic cortical neurons in vitro. Neurosci Lett 2009; 461: 1-6.
47. Lee E, Yim S, Lee SK, Park H. Two transactivation domains of hypoxia-inducible factor-1alpha regulated by the MEK-1/p42/p44 MAPK pathway. Mol Cells 2002; 14: 9-15. (Pubitemid 41582973)
48. Ouyang YB, Tan Y, Comb M, et al. Survival-and death-promoting events after transient cerebral ischemia: phosphorylation of Akt, release of cytochrome C and Activation of caspase-like proteases. J Cereb Blood Flow Metab 1999; 19: 1126-35. (Pubitemid 30167763)
49. Noshita N, Lewén A, Sugawara T, Chan PH. Evidence of phosphorylation of Akt and neuronal survival after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2001; 21: 1442-50. (Pubitemid 33120944)
50. Kamada H, Nito C, Endo H, Chan PH. Bad as a converging signaling molecule between survival PI3-K/Akt and death JNK in neurons after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2007; 27: 521-33.
51. Miyawaki T, Mashiko T, Ofengeim D, et al. Ischemic preconditioning blocks BAD translocation, Bcl-xL cleavage, and large channel activity in mitochondria of postischemic hippocampal neurons. Proc Natl Acad Sci U S A 2008; 105: 4892-7. (Pubitemid 351753842)
52. Chan PH. Future targets and cascades for neuroprotective strategies. Stroke 2004; 35: 2748-50. (Pubitemid 39458385)
53. Woods SA, McGlade CJ, Guha A. Phosphatidylinositol 3′-kinase and MAPK/ERK kinase 1/2 differentially regulate expression of vascular endothelial growth factor in human malignant astrocytoma cells. Neuro Oncol 2002; 4: 242-52.
54. Mahadevan S, Park Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J Food Sci 2008; 73: R14-9. Review.
55. Leistner E, Drewke C. Ginkgo biloba and ginkgotoxin. J Nat Prod 2010; 73: 86-92.
56. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005;12: 10-6. (Pubitemid 40174323)
57. Kumar V. Potential medicinal plants for CNS disorders: an overview. Phytother Res 2006; 20: 1023-35. Review. (Pubitemid 44951704)
58. Madgula VL, Avula B, Yu YB, et al. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo approaches. Planta Med 2010; 76: 599-606.
59. Fang W, Deng Y, Li Y, et al. Blood brain barrier permeability and therapeutic time window of Ginkgolide B in ischemia-reperfusion injury. Eur J Pharm Sci 2010; 39: 8-14.
60. Cho JH, Sung JH, Cho EH, et al. Gingko biloba Extract (EGb 761) prevents ischemic brain injury by activation of the Akt signaling pathway. Am J Chin Med 2009; 37: 547-55.
61. Hong JT, Ryu SR, Kim HJ, et al. Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury. Brain Res Bull 2000; 53: 743-9. (Pubitemid 32120278)
62. Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002; 67: 235-57. Review. (Pubitemid 34880132)
63. He W, Qian Zhong M, Zhu L, et al. Ginkgolides mimic the effects of hypoxic preconditioning to protect C6 cells against ischemic injury by up-regulation of hypoxia-inducible factor-1 alpha and erythropoietin. Int J Biochem Cell Biol 2008; 40: 651-62. (Pubitemid 351288586)
64. Zhu L, Wu XM, Yang L, Du F, Qian ZM. Up-regulation of HIF-1alpha expression induced by ginkgolides in hypoxic neurons. Brain Res 2007; 1166: 1-8. (Pubitemid 47268310)
65. Liu J, Narasimhan P, Yu F, Chan PH. Neuroprotection by hypoxic preconditioning involves oxidative stress-mediated expression of hypoxia-inducible factor and erythropoietin. Stroke 2005; 36: 1264-9. (Pubitemid 40798749)
66. Li YX, Ding SJ, Xiao L, Guo W, Zhan Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 2008; 24: 89-95. (Pubitemid 351738284)
67. Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol 2000; 52: 1563-8. (Pubitemid 32058657)
68. Srinivas NR. Baicalin, an emerging multi-therapeutic agent: pharmacodynamics, pharmacokinetics, and considerations from drug development perspectives. Xenobiotica 2010; 40: 357-67.
69. Lai MY, Hsiu SL, Chen CC, et al. Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae Radix in humans. Biol Pharm Bull 2003; 26: 79-83.
70. Lai MY, Hsiu SL, Tsai SY, et al. Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats. J Pharm Pharmacol 2003; 55: 205-9.
71. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat Rev 2009; 35: 57-68. Review.
72. Huang Y, Tsang SY, Yao X, et al. Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 2005; 5: 177-84. (Pubitemid 40645490)
73. Tarragó T, Kichik N, Claasen B, et al. Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem 2008; 16: 7516-24.
74. Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 2000; 15: D84-90. Review. (Pubitemid 30190730)
75. Liu L, Zhang R, Liu K, et al. Tissue kallikrein protects cortical neurons against in vitro ischemia-acidosis/reperfusion-induced injury through the ERK1/2 pathway. Exp Neurol 2009; 219: 453-65.
76. Hwang KY, Oh YT, Yoon H, et al. Baicalein suppresses hypoxiainduced HIF-1alpha protein accumulation and activation through inhibition of reactive oxygen species and PI 3-kinase/Akt pathway in BV2 murine microglial cells. Neurosci Lett 2008; 444: 264-9.
77. Mander P, Borutaite V, Moncada S, Brown GC. Nitric oxide from inflammatory-activated glia synergizes with hypoxia to induce neuronal death. J Neurosci Res. 2005;79:208-15. (Pubitemid 40116437)
78. Zhou J, Brüne B. NO and transcriptional regulation: from signaling to death. Toxicology 2005; 208: 223-33. Review. (Pubitemid 40192534)
79. Sandau KB, Faus HG, Brüne B. Induction of hypoxia-induciblefactor 1 by nitric oxide is mediated via the PI 3K pathway. Biochem Biophys Res Commun 2000; 278: 263-7.
80. Lu DY, Liou HC, Tang CH, Fu WM. Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha. Biochem Pharmacol 2006; 72: 992-1000.
81. Liu C, Wu J, Xu K, et al. Neuroprotection by baicalein in ischemic brain injury involves PTEN/AKT pathway. J Neurochem 2009; 112: 1500-1512.
82. Perez CA, Wei Y, Guo M. Iron-binding and anti-Fenton properties of baicalein and baicalin. J Inorg Biochem 2009; 103: 326-32.
83. Jiang Z, Zhang Y, Chen X, et al. Activation of Erk1/2 and Akt in astrocytes under ischemia. Biochem Biophys Res Commun 2002; 294: 726-33. (Pubitemid 34694073)
84. Wang Z, Chen X, Zhou L, Wu D, Che X, Yang G. Effects of extracellular signal-regulated kinase (ERK) on focal cerebral ischemia. Chin Med J (Engl) 2003; 116: 1497-503. (Pubitemid 37461663)
85. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH. VEGF Stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke 2009; 40:1467-73.
86. Sawe N, Steinberg G, Zhao H. Dual roles of the MAPK/ERK1/2 cell signaling pathway after stroke. J Neurosci Res 2008; 86: 1659-69. Review. (Pubitemid 351859418)
87. Liu HQ, Li WB, Li QJ, et al. Phosphorylation of ERK1/2 is promoted in brain ischemic preconditioning partly mediated by NO signal pathway. Nitric oxide participates in the induction of brain ischemic tolerance via activating ERK1/2 signaling pathways. Neurochem Res 2006; 31: 967-74.
88. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem 1999; 274: 32631-7. (Pubitemid 129535289)
89. Hur E, Chang KY, Lee E, Lee SK, Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxiainducible factor-1alpha. Mol Pharmacol 2001; 59: 1216-24. (Pubitemid 32381601)
90. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000; 468: 53-8. (Pubitemid 30101681)
91. Li Z, Ya K, Xiao-Mei W, Lei Y, Yang L, Ming QZ. Ginkgolides protect PC12 cells against hypoxia-induced injury by p42/p44 MAPK pathway-dependent upregulation of HIF-1alpha expression and HIF-1DNA-binding activity. J Cell Biochem 2008; 103: 564-75. (Pubitemid 351171927)
92. Amantea D, Fratto V, Maida S, et al. Prevention of Glutamate Accumulation and Upregulation of Phospho-Akt may Account for Neuroprotection Afforded by Bergamot Essential Oil against Brain Injury Induced by Focal Cerebral Ischemia in Rat. Int Rev Neurobiol 2009; 85: 389-405.
93. Wang Q, Zhang QG, Wu DN, Yin XH, Zhang GY. Neuroprotection of selenite against ischemic brain injury through negatively regulating early activation of ASK1/JNK cascade via activation of PI3K/AKT pathway. Acta Pharmacol Sin 2007; 28: 19-27. (Pubitemid 46046622)
94. Wang HY, Wang GL, Yu YH, Wang Y. The role of phosphoinositide- 3-kinase/Akt pathway in propofol-induced postconditioning against focal cerebral ischemia-reperfusion injury in rats. Brain Res 2009; 1297: 177-84.
95. Xu X, Chua CC, Gao J, Hamdy RC, Chua BH. Humanin is a novel neuroprotective agent against stroke. Stroke 2006; 37: 2613-9. (Pubitemid 44454687)
96. Tomaselli B, Nedden SZ, Podhraski V, Baier-Bitterlich G. p42/44 MAPK is an essential effector for purine nucleoside-mediated neuroprotection of hypoxic PC12 cells and primary cerebellar granule neurons. Mol Cell Neurosci 2008; 38: 559-68.
97. Chung H, Seo S, Moon M, Park S. Phosphatidylinositol-3-kinase/Akt/ glycogen synthase kinase-3 beta and ERK1/2 pathways mediate protective effects of acylated and unacylated ghrelin against oxygen-glucose deprivation-induced apoptosis in primary rat cortical neuronal cells. J Endocrinol 2008; 198: 511-21.
98. Triantafyllou A, Liakos P, Tsakalof A, Georgatsou E, Simos G, Bonanou S. Cobalt induces hypoxia-inducible factor-1alpha (HIF-1alpha) in HeLa cells by an iron-independent, but ROS-, PI-3K and MAPK-dependent mechanism. Free Radic Res. 2006; 40:847-56. (Pubitemid 44480495)
99. Nagle DG, Zhou YD. Natural product-based inhibitors of hypoxiainducible factor-1 (HIF-1). Curr Drug Targets 2006; 7: 355-69. Review. (Pubitemid 43744851)